Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials
Executive Summary
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
You may also be interested in...
Coronavirus Vaccine: How Hard Might Development Get? Look At Chikungunya
Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
The latest drug development news and highlights from our FDA Performance Tracker. Vaxchora cholera vaccine is CBER's fourth novel biologic cleared this year; Adamis emergency Epi turned down again.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: